NEW ORLEANS – Patients with severe schizophrenia who fail to respond to treatment with standard doses of second-generation antipsychotics show significant improvement with – and tolerance of – higher maintenance doses of the drugs, new research shows. Dr Juan Jose Fernandez-Miranda The use of [higher doses of] long-acting injectable second-generation antipsychotics shows improvement not only … Read more
Cariprazine (Vraylar) is a safe and effective adjunctive treatment for adults with major depressive disorder (MDD) who have an inadequate response to antidepressant monotherapy, new results from a phase 3 study show. Already approved by the US Food and Drug Administration (FDA) to treat adults with schizophrenia and manic, mixed, or depressive episodes of bipolar … Read more
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Different psychotropic medications are associated with different risks of COVID-19 in hospitalized patients with serious mental illness, a new study suggests. Investigators found that second-generation antipsychotics were associated with a 48% lower risk of COVID-19, while valproic acid was associated with … Read more